Darifenacin, a muscarinic M3 selective receptor antagonist (M3 SRA) for overactive bladder, does not prolong QT/QTc

  • Serra, D. B.
  • Affrime, M. B.
  • Bedigian, M. P.
  • Greig, G.
  • Wang, Y.

  • Novartis Pharmaceuticals Corporation, New Jersey, USA

British Journal of Clinical Pharmacology 59(5):p 633, May 2005.
Copyright © 2005 Blackwell Publishing Ltd.
View full text|Download PDF